Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: geewiz who wrote (349)	12/27/1998 9:13:00 PM
From: Marc Kahn	Read Replies (1) \| Respond to of 534

Hi Art, I also was struck by the efficiency comparison in this statement: <<This enables DNA to be administered into the body by attaching it to microscopic gold particles propelled into the skin at supersonic speed using a helium jet. The method is up to 1,000 times more efficient than conventional injection.>> I believe that the dynamics of this are the same as the use of intramuscular jet injection being used to deliver DNA vaccines. DNA vaccines, and other gene therapies, rely on cellular contact for their uptake. In a conventional injection, there is a bubble of medicine left in the body. The only cells to come into contact with the medicine are those right on the margin of the bubble. With jet injection, the medicine is dispersed through tissue immediately upon penetrating the skin, creating a cloud of medicine. I would not be surprised if that cloud causes the medicine to come into contact with a thousand times more cells, although it does seem like a stretch. It seems to me that preparing an injection by attaching DNA to microscopic gold particles has got to be an expensive prospect. That's why I'm not too concerned about Powderject casting a competitive specter over Bioject. Regards, Marc Kahn